Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc. (DRUG.CN) Financial Performance & Income Statement Overview
Explore the financials of Bright Minds Biosciences Inc. (DRUG.CN), including yearly and quarterly data on income, cash flow, and balance sheets.
Bright Minds Biosciences Inc. (DRUG.CN) Income Statement & Financial Overview
View the income breakdown for Bright Minds Biosciences Inc. DRUG.CN across both annual and quarterly reports.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $18113.00 | $18112.00 |
| Gross Profit | $0.00 | $0.00 | -$18113.00 | -$18112.00 |
| Gross Profit Ratio | ||||
| R&D Expenses | $1.05M | $416055.00 | -$566749.00 | $105180.00 |
| SG&A Expenses | $540928.00 | $351012.00 | $320644.00 | $432644.00 |
| Operating Expenses | $1.62M | $791310.00 | -$254096.00 | $537824.00 |
| Total Costs & Expenses | $1.62M | $791310.00 | -$235983.00 | $555936.00 |
| Interest Income | $4318.00 | $6007.00 | $14987.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $2126.00 |
| Depreciation & Amortization | $21533.00 | $19019.00 | $18113.00 | $18112.00 |
| EBITDA | -$1.60M | -$772291.00 | $249253.00 | -$553904.00 |
| EBITDA Ratio | ||||
| Operating Income | -$3.30M | $0.00 | $235983.00 | -$555940.00 |
| Operating Income Ratio | ||||
| Other Income/Expenses (Net) | $3.35M | -$773441.00 | -$6080.00 | -$18205.00 |
| Income Before Tax | $49610.00 | -$773441.00 | $229903.00 | -$574141.00 |
| Income Before Tax Ratio | ||||
| Income Tax Expense | $0.00 | $0.00 | $0.00 | -$2.00 |
| Net Income | $49610.00 | -$773441.00 | $229903.00 | -$574141.00 |
| Net Income Ratio | ||||
| EPS | $0.008 | -$0.17 | $0.05 | -$0.13 |
| Diluted EPS | $0.007 | -$0.17 | $0.05 | -$0.13 |
| Weighted Avg Shares Outstanding | $6.17M | $4.46M | $4.46M | $4.46M |
| Weighted Avg Shares Outstanding (Diluted) | $6.64M | $4.65M | $4.65M | $4.46M |
Over the last four quarters, Bright Minds Biosciences Inc. achieved steady financial progress, growing revenue from $0.00 in Q2 2024 to $0.00 in Q1 2025. Gross profit stayed firm with margins at N/A in Q1 2025 versus N/A in Q2 2024. Operating income totaled -$3.30M in Q1 2025, maintaining a N/A margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$1.60M. Net income rose to $49610.00, with EPS at $0.008. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan